You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

~ Buy the BREXAFEMME (ibrexafungerp citrate) Drug Profile, 2024 PDF Report in the Report Store ~

brexafemme Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Brexafemme, and when can generic versions of Brexafemme launch?

Brexafemme is a drug marketed by Scynexis and is included in one NDA. There are five patents protecting this drug.

This drug has fifty patent family members in twenty-four countries.

The generic ingredient in BREXAFEMME is ibrexafungerp citrate. One supplier is listed for this compound. Additional details are available on the ibrexafungerp citrate profile page.

DrugPatentWatch® Generic Entry Outlook for Brexafemme

Brexafemme will be eligible for patent challenges on June 1, 2025. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be January 19, 2035. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Try a Trial

Summary for brexafemme
International Patents:50
US Patents:5
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Raw Ingredient (Bulk) Api Vendors: 11
Drug Prices: Drug price information for brexafemme
What excipients (inactive ingredients) are in brexafemme?brexafemme excipients list
DailyMed Link:brexafemme at DailyMed
Drug patent expirations by year for brexafemme
Drug Prices for brexafemme

See drug prices for brexafemme

DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for brexafemme
Generic Entry Date for brexafemme*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for brexafemme

US Patents and Regulatory Information for brexafemme

brexafemme is protected by six US patents and three FDA Regulatory Exclusivities.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of brexafemme is ⤷  Try a Trial.

This potential generic entry date is based on patent ⤷  Try a Trial.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting brexafemme

Salts and polymorphs of SCY-078
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial

Salts and polymorphs of SCY-078
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)

Salts and polymorphs of SCY-078
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)


Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES

Antifungal agents
Patent Number: ⤷  Try a Trial
Patent Expiration: ⤷  Try a Trial
Patented Use: TREATMENT OF ADULT AND POST-MENARCHAL PEDIATRIC FEMALES WITH VULVOVAGINAL CANDIDIASIS (VVC)

FDA Regulatory Exclusivity protecting brexafemme

NEW CHEMICAL ENTITY
Exclusivity Expiration: ⤷  Try a Trial

REDUCTION IN THE INCIDENCE OF RECURRENT VULVOVAGINAL CANDIDIASIS (RVVC) IN ADULT AND POST-MENARCHAL PEDIATRIC FEMALES
Exclusivity Expiration: ⤷  Try a Trial

GENERATING ANTIBIOTIC INCENTIVES NOW
Exclusivity Expiration: ⤷  Try a Trial

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y ⤷  Try a Trial
Scynexis BREXAFEMME ibrexafungerp citrate TABLET;ORAL 214900-001 Jun 1, 2021 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for brexafemme

When does loss-of-exclusivity occur for brexafemme?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Croatia

Patent: 0220544
Estimated Expiration: ⤷  Try a Trial

Denmark

Patent: 47711
Estimated Expiration: ⤷  Try a Trial

Eurasian Patent Organization

Patent: 6874
Estimated Expiration: ⤷  Try a Trial

Patent: 1791645
Estimated Expiration: ⤷  Try a Trial

European Patent Office

Patent: 47711
Estimated Expiration: ⤷  Try a Trial

Patent: 39684
Estimated Expiration: ⤷  Try a Trial

Hong Kong

Patent: 47196
Estimated Expiration: ⤷  Try a Trial

Hungary

Patent: 58721
Estimated Expiration: ⤷  Try a Trial

Lithuania

Patent: 47711
Estimated Expiration: ⤷  Try a Trial

Poland

Patent: 47711
Estimated Expiration: ⤷  Try a Trial

Portugal

Patent: 47711
Estimated Expiration: ⤷  Try a Trial

Serbia

Patent: 234
Estimated Expiration: ⤷  Try a Trial

Slovenia

Patent: 47711
Estimated Expiration: ⤷  Try a Trial

Spain

Patent: 13111
Estimated Expiration: ⤷  Try a Trial

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering brexafemme around the world.

Country Patent Number Title Estimated Expiration
China 111093655 在酸性PH值下具有经增强活性的抗真菌剂 (ANTIFUNGAL AGENTS WITH ENHANCED ACTIVITY IN ACIDIC PH) ⤷  Try a Trial
Poland 3661503 ⤷  Try a Trial
Finland 3661503 ⤷  Try a Trial
South Korea 20200044823 산성 pH에서 증진된 활성을 갖는 항진균제 ⤷  Try a Trial
Slovenia 3661503 ⤷  Try a Trial
European Patent Office 4039684 NOUVEAUX SELS ET POLYMORPHES DE SCY-078 (NOVEL SALTS AND POLYMORPHS OF SCY-078) ⤷  Try a Trial
European Patent Office 2326181 AGENTS ANTIFONGIQUES (ANTIFUNGAL AGENTS) ⤷  Try a Trial
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.